668990-76-9

Basic information

• Product Name: α-Tosyl-(2,6-difluorobenzyl)isocyanide
• Synonyms: a-Tosyl-(2,6-difluorobenzyl)isocyanide;1,3-Difluoro-2-(isocyano(tosyl)methyl)benzene;α-Tosyl-(2,6-difluorobenzyl)isocyanide
• CAS NO: 668990-76-9
• Molecular Formula: C₁₅H₁₁F₂NO₂S
• Molecular Weight: 307.319
• Mol File: 668990-76-9.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• CAS DataBase Reference: α-Tosyl-(2,6-difluorobenzyl)isocyanide(CAS DataBase Reference)
• NIST Chemistry Reference: α-Tosyl-(2,6-difluorobenzyl)isocyanide(668990-76-9)
• EPA Substance Registry System: α-Tosyl-(2,6-difluorobenzyl)isocyanide(668990-76-9)

Safety Data

• Hazardous Substances Data: 668990-76-9(Hazardous Substances Data)

Usage

General Description

α-Tosyl-(2,6-difluorobenzyl)isocyanide is a chemical compound with the molecular formula C15H12F2NO2S. It is an isocyanide derivative that contains a tosyl group and a 2,6-difluorobenzyl group attached to the isocyanide carbon. It is commonly used in organic synthesis as a versatile building block for the preparation of various biologically active compounds. α-Tosyl-(2,6-difluorobenzyl)isocyanide is known for its ability to participate in a variety of chemical reactions, including cycloadditions and metal-catalyzed transformations, making it a valuable tool for the synthesis of complex molecules. Additionally, α-Tosyl-(2,6-difluorobenzyl)isocyanide has been studied for its potential application in the development of new pharmaceuticals and materials.

Upstream product

• 668990-75-8 N-[(2,6-difluoro-phenyl)-(toluene-4-sulfonyl)-methyl]-formamide 

Relevant articles and documents

DI AND TRIFLUORO-TRIAZOLO-PYRIDINES ANTI-INFLAMMATORY COMPOUNDS

The present invention relates to novel triazolo-pyridines of the formula (I) wherein R1 is fluoro; s is an integer from two to three; R2 is (C3-C6)cycloalkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (Cl-C4)alkyl, hydroxy, (Cl-C6)alkoxy and (C1-C6)alkyl-(C=O)-0-; or R2 is (Cl-C6)alkyl optionally substituted by one or two moieties independently selected from the group consisting of halo, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy and (C1-C6)alkyl-(C=O)-0-; with the proviso that said compound of formula (I) cannot be 6-[4-(2,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; or 6-[4-(3,4-Difluoro-phenyl)-oxazol-5-yl]-3-isopropyl-[1,2,4]triazolo[4,3-a]pyridine; to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are potent inhibitors of MAP kinases, preferably p38 kinase. They are useful in the treatment of inflammation, osteoarthritis, rheumatoid arthritis, cancer, repurfusion or ischemia in stroke or heart attack, autoimmune diseases and other disorders.